IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alcobra, Ltd., and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / February 24, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Alcobra, Ltd. (“Alcobra” or the “Company”) (NASDAQ: ADHD). Investors, who purchased or otherwise acquired shares between August 13, 2015 and January 17, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 18, 2017 lead plaintiff deadline.

If you purchased shares of Alcobra during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

Alcobra is a biopharmaceutical company that makes and markets oral drug candidates. On January 17, 2017, Alcobra disclosed that the Company’s attention deficit hyperactivity disorder drug, Metadoxine Extended Release, could not reach its primary endpoint during a Phase 3 trial. When this information was disclosed to the public, the value of Alcobra declined, causing investors harm.

If you wish to learn more about this lawsuit at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 455979